Integra LifeSciences financials
$16.64+2.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B | $1.37B | $1.52B | $1.47B | $1.19B | $992.1M |
| Gross profit | $831.6M | $882.1M | $884.7M | $970.3M | $944.6M | $851.0M | $952.9M | $900.9M | $752.7M | $643.0M |
| Gross margin | 50.9% | 54.8% | 57.4% | 62.3% | 61.2% | 62.0% | 62.8% | 61.2% | 63.3% | 64.8% |
| Operating income | -$493.4M | $28.4M | $111.5M | $238.9M | $197.2M | $151.4M | $93.8M | $111.0M | $44.8M | $115.3M |
| Net income | -$516.5M | -$6.9M | $67.7M | $180.6M | $169.1M | $133.9M | $50.2M | $60.8M | $64.7M | $74.6M |
| Net margin | −31.6% | −0.4% | 4.4% | 11.6% | 11.0% | 9.8% | 3.3% | 4.1% | 5.4% | 7.5% |
| Diluted EPS | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 | $1.57 | $0.58 | $0.72 | $0.82 | $0.94 |
| EBITDA | $169.8M | $169.3M | $235.0M | $357.2M | $317.1M | $267.4M | $203.2M | $221.7M | $133.7M | $188.0M |
| Operating cash flow | $50.4M | $129.4M | $140.0M | $264.5M | $314.6M | $203.8M | $232.2M | $200.6M | $115.0M | $116.4M |
| Free cash flow | -$31.1M | $25.0M | $73.1M | $222.1M | $266.6M | $164.9M | $162.6M | $122.9M | $71.5M | $69.1M |
| Diluted shares | 76.7M | 77.0M | 80.3M | 83.5M | 85.5M | 85.2M | 86.5M | 84.0M | 79.1M | 79.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $235.0M | $246.4M | $276.4M | $456.7M | $513.4M | $470.2M |
| Short-term investments | $28.7M | $27.2M | $32.7M | $0.00 | — | — |
| Total debt | $1.86B | $1.80B | $1.50B | $1.44B | $1.55B | $1.55B |
| Total assets | $3.60B | $4.04B | $3.78B | $3.89B | $3.78B | $3.62B |
| Total liabilities | $2.56B | $2.49B | $2.19B | $2.09B | $2.10B | $2.10B |
| Shareholders' equity | $1.04B | $1.55B | $1.59B | $1.80B | $1.68B | $1.51B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology